Gufic Biosciences Limited has announced its quarterly earnings conference call to discuss Q3FY26 financial results with investors and analysts. The pharmaceutical company has scheduled the investor engagement for February 16, 2026, providing stakeholders an opportunity to gain insights into its recent performance and business outlook.

Conference Call Details

The earnings call has been scheduled with specific timing and access arrangements to accommodate both domestic and international participants.

Regulatory Compliance and Communication

Gufic Biosciences has formally notified both major Indian stock exchanges about the scheduled earnings call. The company communicated this information to BSE Limited and National Stock Exchange of India Limited on February 10, 2026, ensuring compliance with regulatory requirements.

The notification was made pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Compliance Officer Ami Shah signed the official communication to both exchanges.

Access and Participation Options

The company has arranged multiple access methods for participants to join the earnings discussion. A pre-registration link has been provided for advance registration, while international dial-in numbers ensure global accessibility.

Call Agenda and Format

During the earnings conference call, company officials will provide comprehensive coverage of key business areas. The session will include discussions on business background, prospects, and detailed analysis of financial performance for the quarter ended.

The interactive format will allow participants to engage directly with management through a question-and-answer session. This approach enables investors and analysts to seek clarification on specific aspects of the company's performance and strategic direction.

Gufic biosciences Limited has received an income tax demand notice of ₹4.33 crores for Assessment Year 2024-25, the pharmaceutical company informed stock exchanges on January 20, 2026. The demand was issued under Section 156 of the Income Tax Act, 1961, following a computation under Section 143(1)(a) due to disallowance of expenditure.

Tax Demand Details

The Income Tax Department raised the demand aggregating to ₹4,33,36,680 based on expenditure disallowances during the assessment process. The company received the order dated December 22, 2025, on January 19, 2026, and promptly disclosed the information to comply with SEBI listing regulations.

Company's Response Strategy

Gufic Biosciences plans to challenge the tax demand through the appellate process. The company intends to file an appeal before the Commissioner of Income Tax (Appeal) within the time limit prescribed under the Income Tax Act. Management expressed confidence in achieving a favorable outcome based on the case merits, prevailing law, and advice from tax advisors.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The company provided comprehensive details as required under the SEBI Master Circular dated November 11, 2024, ensuring transparency with stakeholders regarding the tax proceedings.

Financial Impact Assessment

While the demand represents a significant amount, the company's assessment suggests potential for successful appeal. Gufic Biosciences emphasized that based on legal advice and case merits, they remain hopeful of a favorable resolution at the appellate authority level. The company will continue to monitor the proceedings and keep stakeholders informed of any material developments.